Baudax Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $3.15 million
- Book Value:
- Revenue TTM:
- $1.27 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Baudax Bio Inc had its IPO on 2019-11-22 under the ticker symbol BXRX.
The company operates in the Healthcare sector and Biotechnology industry. Baudax Bio Inc has a staff strength of 9 employees.
Shares of Baudax Bio Inc opened at $0.52 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.52 - $0.56, and closed at $0.55.
This is a +5.77% increase from the previous day's closing price.
A total volume of 391,509 shares were traded at the close of the day’s session.
In the last one week, shares of Baudax Bio Inc have increased by +0.73%.
Baudax Bio Inc's Key Ratios
Baudax Bio Inc has a market cap of $3.15 million, indicating a price to book ratio of 0.6815 and a price to sales ratio of 1.0493.
In the last 12-months Baudax Bio Inc’s revenue was $1.27 million with a gross profit of $-5740000 and an EBITDA of $-32649000. The EBITDA ratio measures Baudax Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Baudax Bio Inc’s operating margin was -2584.95% while its return on assets stood at -73.38% with a return of equity of -4772.59%.
In Q1, Baudax Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.5%.
Baudax Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-99.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Baudax Bio Inc’s profitability.
Baudax Bio Inc stock is trading at a EV to sales ratio of 3.9179 and a EV to EBITDA ratio of -1.6268. Its price to sales ratio in the trailing 12-months stood at 1.0493.
Baudax Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.07 million
- Total Liabilities
- $12.37 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Baudax Bio Inc ended 2023 with $7.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.07 million while shareholder equity stood at $-7313000.00.
Baudax Bio Inc ended 2023 with $0 in deferred long-term liabilities, $12.37 million in other current liabilities, 26000.00 in common stock, $-179500000.00 in retained earnings and $2.13 million in goodwill. Its cash balance stood at $3.80 million and cash and short-term investments were $3.80 million. The company’s total short-term debt was $6,000,000 while long-term debt stood at $1.43 million.
Baudax Bio Inc’s total current assets stands at $4.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.84 million and inventory worth $0.
In 2023, Baudax Bio Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Baudax Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Baudax Bio Inc stock is currently trading at $0.55 per share. It touched a 52-week high of $37.7206 and a 52-week low of $37.7206. Analysts tracking the stock have a 12-month average target price of $24.
Its 50-day moving average was $1.2 and 200-day moving average was $5.44 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.
Around 6.2% of the company’s stock are held by insiders while 4600.7% are held by institutions.
Frequently Asked Questions About Baudax Bio Inc
Similar Industry Stocks (Biotechnology)
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.